TuHURA Biosciences, Inc./NV — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TuHURA Biosciences, Inc./NV filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2012 | Jun 30, 2012 | $0 | Dec 20, 2012 |
| FY2012 | Jun 30, 2011 | $0 | Dec 20, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.05M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($21.68M) | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | ($8.32M) | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | ($29.32M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($14.65M) | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | ($22.66M) | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | ($38.30M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($9.13M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($8.05M) | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | $11.14M | Sep 9, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Jun 30, 2012 | ($982) | Dec 20, 2012 |
| FY2012 | Jun 30, 2011 | ($6.8K) | Dec 20, 2012 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.34M | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | $2.66M | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | $9.40M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $9.31M | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | $15.17M | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | $11.82M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $3.63M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $3.66M | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | ($7.13M) | Sep 9, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.63M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.73M) | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | ($7.18M) | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | ($11.95M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($11.87M) | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | ($20.39M) | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | ($18.86M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($7.93M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($6.33M) | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | ($9.85M) | Sep 9, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.1K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $79.2K | Mar 31, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $19.97M | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | $6.20M | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | $4.36M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $3.98M | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | $15.95M | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | $13.54M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $2.94M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $4.04M | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | $7.07M | Sep 9, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.42M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.37M | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | $2.45M | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | $5.92M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $3.25M | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | $4.15M | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | $2.96M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $2.68M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $2.07M | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | $1.64M | Sep 9, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.59M | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | $3.76M | Oct 7, 2024 |
| FY2025 | Dec 31, 2023 | ($1.56M) | Mar 31, 2026 |
| FY2024 | Jun 30, 2023 | $731.0K | Oct 7, 2024 |
| FY2024 | Dec 31, 2022 | $12.30M | Mar 31, 2025 |
| FY2024 | Jun 30, 2022 | $11.80M | Oct 7, 2024 |
| FY2023 | Jun 30, 2021 | $10.58M | Sep 18, 2023 |
| FY2022 | Jun 30, 2020 | $263.0K | Sep 27, 2022 |
| FY2021 | Jun 30, 2019 | $1.97M | Sep 28, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.74M | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($141.18M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($111.12M) | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | ($159.88M) | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | ($88.47M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($151.38M) | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | ($136.36M) | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | ($111.23M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($69.72M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($60.58M) | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | ($52.44M) | Sep 9, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $12.66M | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | $4.91M | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $1.54M | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | $11.78M | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | $10.54M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $2.39M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $3.72M | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | $5.97M | Sep 9, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jun 30, 2018 | $1.1K | Sep 9, 2019 |
| FY2018 | Jun 30, 2017 | $28.1K | Sep 24, 2018 |
| FY2017 | Jun 30, 2016 | $693.7K | Sep 27, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Jun 30, 2024 | 0 | Oct 7, 2024 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | (9) | Oct 7, 2024 |
| FY2023 | Jun 30, 2022 | (25) | Sep 18, 2023 |
| FY2022 | Jun 30, 2021 | (1) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | 3 | Sep 18, 2020 |
| FY2019 | Jun 30, 2018 | 5 | Sep 9, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2015 | Jun 30, 2015 | 0 | Nov 16, 2015 |
| FY2015 | Jun 30, 2014 | 0 | Nov 16, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 12.17M | Mar 31, 2026 |
| FY2025 | Oct 18, 2024 | 42.03M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 12.17M | Mar 31, 2025 |
| FY2019 | Jun 30, 2019 | 7,813 | Sep 9, 2019 |
| FY2019 | Jun 30, 2018 | 91,276 | Sep 9, 2019 |
| FY2018 | Jun 30, 2017 | 982,761 | Sep 24, 2018 |
| FY2017 | Jun 30, 2016 | 1.01M | Sep 27, 2017 |
| FY2016 | Jun 30, 2015 | 1.06M | Sep 13, 2016 |
| FY2015 | Jun 30, 2014 | 35.99M | Nov 16, 2015 |